Clinical Trials · NCT00637273
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 514
- Start date
- Jan 2008
- Locations
- 62 sites, 3 countries
- Primary endpoint
- Change in HbA1c From Baseline to Week 26